Cardiovascular Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
U.S. company to test use of obesity/smoking pill for heart disease
December 7th, 2004
Not content with having a drug that might merely fight obesity and smoking, the company developing this eagerly anticipated pill will soon launch studies to see if it can treat and prevent clogged arteries and heart disease.
The reason the drug looks promising is that even the one-third of people who didn't lose weight on rimonabant, or Acomplia, still had improvements in cholesterol and other heart-disease risk factors, said Douglas Greene, MD, vice president for corporate and regulatory affairs for Sanofi-Aventis, the French company developing the drug.
He also gave the first details on its safety and side effects, including the one major...
Source: Cardiovascular Business Week (2004-12-07)
|
|
|
